Kewaunee Scientific vs Mesa Laboratories
KEQU and MLAB side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KEQU and MLAB compare
Mesa Laboratories is the larger company, worth 7.4 times as much as Kewaunee Scientific ($750M against $101M).
On earnings, Kewaunee Scientific is cheaper: it trades at 12.7× trailing earnings, against 158× for Mesa Laboratories.
Kewaunee Scientific grew revenue faster over the last twelve months (5.3% versus 3.0% for Mesa Laboratories).
Kewaunee Scientific keeps more of each dollar of sales as profit, with a net margin of 3.0% compared with 1.9% at Mesa Laboratories.
Mesa Laboratories pays a dividend yielding 0.48%; Kewaunee Scientific does not pay one.
Kewaunee Scientific scores higher on the StockData Score (14 against 11 for Mesa Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KEQU | MLAB |
|---|---|---|
| Size and price | ||
| Market cap | $101M | $750M |
| Share price | $35.05 | $134.09 |
| Change, 1 year | −12.5% | 76.8% |
| Change, 5 years | 170% | −57.1% |
| Beta (5Y) | 0.79 | 1.00 |
| Employees | – | 717 |
| StockData Score | ||
| Total score | 14 (better) | 11 |
| Valuation score | 5 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 4 | 4 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 12.7× (better) | 158× |
| P/S | 0.4× (better) | 3.0× |
| P/B | 1.4× (better) | 4.0× |
| EV/EBITDA | 5.3× (better) | 32.0× |
| P/FCF | 9.3× (better) | 14.2× |
| PEG | 0.09 (better) | 1.71 |
| FCF yield | 10.7% (better) | 7.0% |
| Fair value | $76.96 | $71.16 |
| Margin of safety | 54.5% (better) | −88.4% |
| Growth | ||
| Revenue growth (TTM) | 5.3% (better) | 3.0% |
| Revenue growth, 5Y average | 13.8% (better) | 13.2% |
| Net income growth (TTM) | −33.1% | – |
| EPS growth (TTM) | −33.2% | – |
| EPS growth, 5Y average | – | 13.6% |
| Profitability | ||
| Gross margin | 28.6% | 64.2% (better) |
| Operating margin | 5.4% | 9.0% (better) |
| Net margin | 3.0% (better) | 1.9% |
| FCF margin | 3.9% | 21.2% (better) |
| Return on equity | 11.6% (better) | 2.7% |
| Return on invested capital | 13.1% (better) | 7.5% |
| Financial health | ||
| Debt / equity | 0.25 | – |
| Net debt / EBITDA | 0.50 | – |
| Interest coverage | 4.4× (better) | 2.1× |
| Current ratio | 2.20 (better) | 1.79 |
| Altman Z-score | 3.42 (better) | 2.24 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.48% |
| Payout ratio | – | 73.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 0.48% (better) |
| Ownership | ||
| Held by institutions | 41.4% | 89.9% |
| Held by insiders | 16.1% | 3.6% |
| Insider net buying, 12 months | −$293K | −$216K (better) |
| Short interest, % of float | 1.6% | 7.0% |
Go deeper
- KEQU stock overview
- KEQU income statement
- KEQU valuation and score
- MLAB stock overview
- MLAB income statement
- MLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.